Introduction {#s1}
============

With 639,000 deaths per year worldwide, colorectal cancer is the third most common form of cancer and the second leading cause of cancer-related deaths in the Western world (WHO, February 2009, <http://www.who.int/mediacentre/factsheets/fs297/en/>) and in China [@pone.0070307-Fodde1], [@pone.0070307-Chiu1]. To date, susceptibility to colorectal cancer has been characterized by the identification of rare inherited mutations in a small number of established genes such as mutations of the *APC* gene, a gene first identified as the familial adenomatous polyposis (FAP) locus gene [@pone.0070307-Kinzler1] that contributes to colorectal tumorigenesis [@pone.0070307-Fodde1], [@pone.0070307-Sparks1]. SNPs (single nucleotide polymorphisms) are the most frequent type of variation in the human genome, occurring once every several hundred base pairs throughout the genome [@pone.0070307-Cargill1].

Recent studies have demonstrated the potential power of deep re-sequencing of candidate genes in human populations to detect rare variants and aid in the understanding of complex human traits [@pone.0070307-Topol1]. Traditionally, cancer genome re-sequencing has been performed using exon amplification and conventional Sanger sequencing [@pone.0070307-Wood1]--[@pone.0070307-Sjoblom1]. More recently, the whole genome or whole exome (by exome capturing) has been used due to technological advances and reduced cost in next generation sequencing [@pone.0070307-Lin1]--[@pone.0070307-Mardis1]. For example, Bass *et al.* applied whole genome sequencing to sequence the tumors of 9 CRC patients and identified 11 in-frame gene fusion events including the fusion of VTI1A and TCF7L2, which was found in 3 of 97 colorectal cancers [@pone.0070307-Bass1]. The Cancer Genome Atlas Network recently performed exome capture DNA sequencing of colorectal cancers and identified frequently mutated genes including APC, TP53, KRAS, PIK3CA, FBXW7, SMAD4, TCF7L2, NRAS, ARID1A, SOX9 and FAM123B (WTX) genes [@pone.0070307-Network1].

Moreover, instead of capturing the whole exome, targeted capture of selected genes of interest will reduce cost and potentially move NGS into clinical practice. For example, Pritchard *et al.* developed Coloseq, in which selected regions of 1.1 Mb of DNA including 209 kb in *MLH1*, *MSH2*, *MSH6*, *PMS2*, *EPCAM*, *APC*, and *MUTYH* were targeted, captured and subjected to NGS [@pone.0070307-Pritchard1]. The authors were able to identify 28/28 (100%) pathogenic mutations in MLH1, MSH2, MSH6, PMS2, EPCAM, APC, and MUTYH [@pone.0070307-Pritchard1].

We were interested in the targeted capture of genomic regions including the promoters and intronic regions of genes related to a pathway or a network of genes with certain characteristics to understand cancer biology. There are several advantages to this approach: 1) the genes can be selected based on biology or a hypothesis; 2) mutations in promoter and intronic regions, which have recently been suggested to have important regulatory roles, can be investigated; and 3) the technique is less expensive than whole genome or whole exome sequencing. Therefore, we designed custom high-density oligonucleotide microarrays (NimbleGen Inc.) to capture a total of approximately 1.7 Mb target regions comprising the genomic regions of 28 genes related to colorectal cancer including the exonic, intronic, 10 kb upstream and 5 kb downstream sequences followed by analysis using the Illumina Genome Analyzer. The selected genes include those belonging to the WNT signaling pathway, as well as important transcription factors or colon-specific genes that are over expressed in CRC.

Results {#s2}
=======

Targeted Re-sequencing of Genomic Regions Including Promoters of the Key WNT Pathway and Other CRC-related Genes {#s2a}
----------------------------------------------------------------------------------------------------------------

As the WNT signaling pathway is a critical pathway implicated in CRC [@pone.0070307-Bienz1], we selected two WNT pathway genes (<http://www.genome.jp/kegg/pathway/hsa/hsa04310.html>) to begin our investigation. In addition, we selected 22 important transcription factors (transcription regulator activity GO:0030528) and four colon-specific or enriched genes [@pone.0070307-Jongeneel1] that are over expressed in cancer based on data generated in the laboratory as well as data available in the public domain (e.g. GSE8671, GSE15960, GSE24551, GSE41258 from the GEO database). The final list of the selected 28 genes is shown in [Table 1](#pone-0070307-t001){ref-type="table"} with annotations.

10.1371/journal.pone.0070307.t001

###### The sequence coverage of 28 selected genes and number of SNPs in CRC and CRN identified by NGS.

![](pone.0070307.t001){#pone-0070307-t001-1}

                                                                                                                                                       NG coverage (%)^a^   total coverage (%)^b^   folds coverage (x)^c^   no. SNPs^d^   SNP rate (‰)^e^                                         
  --------- -------- ---------------------------- --------------------------------------------------------------------------------------------------- -------------------- ----------------------- ----------------------- ------------- ----------------- ---- ----- ----- ----- ------- ------- -------
  APC         324     chr5∶112063584--112186935                                       Adenomatosis polyposis coli                                            119.2                  119.3                   99.87              99.99            46          46   135   151   166   1.094   1.224   1.346
  AXIN1       8312       chr16∶327440--407464                                                   Axin 1                                                       132.8                  136.4                   95.45              98.07            19          40   49    72    90    0.612    0.9    1.125
  DAXX        1616     chr6∶33276335--33295791                                        Death-associated protein 6                                             134.6                  138.9                   95.68              98.76            22          39    8    19    20    0.411   0.977   1.028
  ETS2        2114     chr21∶40167231--40201879                       V-ets erythroblastosis virus E26 oncogene homolog 2 (avian)                            112.0                  112.4                   98.9               99.29            45          54   78    73    88    2.251   2.107   2.54
  ETV4        2118     chr17∶41595212--41628762                         Ets variant gene 4 (E1A enhancer binding protein, E1AF)                              121.8                  123.0                   99.05               100             29          48   32    45    47    0.954   1.341   1.401
  FLI1        2313    chr11∶128553989--128687310                                  Friend leukemia virus integration 1                                        106.3                  106.8                   99.53               100             45          57   222   237   265   1.665   1.778   1.988
  FUBP1       8880     chr1∶78390603--78449777                               Far upstream element (FUSE) binding protein 1                                   119.4                  119.5                   99.99               100             46          47   61    63    87    1.031   1.065   1.47
  GTF2A2      2958     chr15∶59921065--59954719                               General transcription factor IIA, 2, 12 kDa                                    134.5                  135.5                   98.71              99.44            39          45   73    89    99    2.169   2.644   2.942
  HIPK2      28996    chr7∶139247375--139426847                                Homeodomain interacting protein kinase 2                                      116.5                  116.9                   83.47              83.8             35          46   134   138   176   0.764   0.787   1.003
  HMGA1       3159     chr6∶34194650--34219008                                       High mobility group AT-hook 1                                           107.7                  115.2                   88.37              94.52            22          39   13    21    24    0.534   0.862   0.985
  KAT5       10524     chr11∶65469489--65492074                                      K(lysine) acetyltransferase 5                                           110.9                  111.2                   95.28              99.29            25          40    8    13    16    0.354   0.576   0.708
  LRTOMT     220074    chr11∶71798368--71819433                  leucine rich transmembrane and 0-methyltransferase domain containing                        145.2                  145.9                   99.82               100             35          57   24    30    32    1.139   1.424   1.519
  MDM2        4193     chr12∶69191980--69239214                 Mdm2, transformed 3T3 cell double minute 2, p53 binding protein (mouse)                      103.7                  104.9                   99.16              99.64            34          39   26    29    40    0.55    0.614   0.847
  MSX2        4488    chr5∶174141575--174162901                                             Msh homeobox 2                                                   117.6                  119.4                   98.47              99.67            31          48   29    31    38    1.36    1.454   1.782
  NR3C1       2908    chr5∶142647496--142820077                Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)                     138.0                  139.8                   98.1               99.61            45          46   184   278   333   1.066   1.611   1.93
  PPARA       5465     chr22∶46536499--46644653                            Peroxisome proliferator-activated receptor alpha                                  123.8                  123.8                   98.19              99.49            29          44   44    62    78    0.407   0.573   0.721
  PRKCDBP    112464     chr11∶6330176--6346740                                  Protein kinase C, delta binding protein                                      145.7                  149.1                   99.84               100             32          42   19    30    35    1.147   1.811   2.113
  RNF25      64320    chr2∶219518588--219541781                                         Ring finger protein 25                                               108.9                  112.2                   99.96               100             35          52   11    15    19    0.474   0.647   0.819
  SMARCA4     6597     chr19∶11061606--11177953    SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4         131.7                  132.0                   97.11              99.35            20          42   55    78    90    0.473   0.67    0.774
  SOX4        6659     chr6∶21583972--21603847                                   SRY (sex determining region Y)-box 4                                        130.3                  136.6                   94.54              97.33            35          43   17    15    24    0.855   0.755   1.207
  STAT5A      6776     chr17∶40429565--40468958                           Signal transducer and activator of transcription 5A                                122.8                  124.8                   94.91              99.52            20          41   25    35    37    0.635   0.888   0.939
  TCF3        6929      chr19∶1599293--1655277               Transcription factor 3 (E2A immunoglobulin enhancer binding factors E12/E47)                    121.4                  124.9                   95.71              98.43            12          35   108   138   153   1.929   2.465   2.733
  TFDP1       7027    chr13∶114229056--114300499                                       Transcription factor Dp-1                                             120.6                  121.6                   98.27              99.1             32          52   27    45    50    0.378   0.63     0.7
  TNKS2      80351     chr10∶93548069--93630032                   Tankyrase, TRF1-interacting ankyrin-related ADP-ribose polymerase 2                        142.9                  148.9                   97.93              99.48            42          45   34    48    57    0.415   0.586   0.695
  TRIM28     10155     chr19∶59045836--59067082                                     Tripartite motif-containing 28                                           129.5                  149.6                   85.28              98.48            17          39   65    81    105   3.059   3.812   4.942
  VAV1        7409      chr19∶6762722--6862371                                 Vav 1 guanine nucleotide exchange factor                                      171.7                  175.0                   96.43              98.32            21          37   73    87    116   0.733   0.873   1.164
  YBX1        4904     chr1∶43138072--43173073                                          Y box binding protein 1                                              116.3                  117.4                   98.04              98.97            45          52   25    25    31    0.714   0.714   0.886
  ZNF3        7551     chr7∶99651851--99684363                                           Zinc finger protein 3                                               166.8                  169.3                   98.14              99.61            28          44   21    20    26    0.646   0.615    0.8

NG coverage (%): the percentage of regions covered by final reads out of the whole NimbleGen captured regions for each gene, including 10-kb upstream and 5-kb downstream.

total coverage (%): the percentage of regions covered by final reads out of the whole designed regions for each gene.

folds coverage (x): the average read depth.

no. SNPs: the total SNPs identified for the gene.

SNP rate (‰): the average count of SNP in a 1k-bp window.

The chromosome names and locations of the genomic regions that were captured for each gene.

To reduce expenses, we first sequenced a pool of 30 CRC tissues (the CRC pool) and a pool of 30 adjacent normal tissues (the CRN pool) and then validated the SNPs identified using PCR or Sequenom's technologies. We created a custom oligo array using NimbleGen technology to capture the target sequences. The total length of the target genomic regions designed was 1.7 Mbp. The captured DNAs were subjected to sequencing using the Illumina Genome Analyzer. After removing PCR duplicates from the raw sequences, the average coverage ranged from 32x to 45x, and the coverage by sequence length for the targeted regions of each gene ranged from 83.5 to 100%. The coverage for the different regions of the target genes differed, which might be due to the property of NimbleGen sequence capture technology, sequence complexity or other uncharacterized factors. The raw sequencing data was deposited in the NCBI sequence read archive (SRA) under accession number SRX277359.

We tabulated the coverages of all 28 genes by comparing to regions covered by the designed probes or to the total targeted regions including promoters and 3′ distal regions ([Table 1](#pone-0070307-t001){ref-type="table"}) to calculate the capture efficiency of the NimbleGen approach. Measured by the targeted regions, the median coverages was 98.1 and 99.5% for the CRC and the CRN tissues respectively, and ranging from 83.5 to 100% ([Table 1](#pone-0070307-t001){ref-type="table"}). In the NinbleGen probe design, the probes were not designed as overlapping oligos to cover the complete regions, but rather as probes that spaced among the target regions with specific characteristics optimized to DNA capture. The coverage calculated by the regions covered by the designed probes all exceed 100% ([Table 1](#pone-0070307-t001){ref-type="table"}), suggesting that the capture probes captured adjacent sequences in addition to their complementary sequences, which resulted in that the sequenced regions actually extended beyond the regions that were covered by the probes.

The GC content was computed for each position of the reference sequences centered in an 81-bp window in order to investigate whether the coverages were affected by the GC content of the captured regions. The coverage for each position was counted after removing duplicate sequences. Sufficient coverage of \>40X was achieved for regions with a GC content between approximately 15--75% ([Figure 1A, 1B](#pone-0070307-g001){ref-type="fig"}). We next studied whether the difference in the coverage affected the detection frequency of sequence variations. We computed the Spearman correlation for the SNP count and the corresponding coverage using R ([www.r-project.org](http://www.r-project.org)). Here, the coverage was counted after removing sequence duplicates. The correlation coefficients were −0.51 and −0.38 for CRC and CRN samples, respectively, suggesting little correlation between SNP detection and read coverage. We further computed whether the SNP percentage accounted for the total SNPs with different coverages ([Figure 1C](#pone-0070307-g001){ref-type="fig"}). We found that the detection frequency remained flat when the sequence coverage increased from 40X to 60X for the CRC tissues. However, we found that the detection frequency in the normal tissue pools increased when the sequence coverage reached approximately 55X to 65X ([Figure 1C](#pone-0070307-g001){ref-type="fig"}). These differences might suggest a higher heterogeneity among the normal tissue pool than the CRC tissue pool, which may be explained by a similar tumor biology or mutation profiles among the CRC tissues. The detecting frequency dropped when the sequence coverage was greater than 65X, likely due to false high coverage generated for the repeated sequences for these regions.

![GC content, coverage and SNP count.\
(A) The GC content and coverage in CRC (colorectal cancer) tissue. (B) The GC content and coverage in CRN (colorectal normal tissue) tissue. (C) The relationship between sequence coverage and SNP detection. Red line shows the sequence coverage and percentage of SNPs detected at that coverage in CRC pool, and green line in CRN pool (D) Venn diagram of SNPs for CRC and CRN samples. (E) An overview of SNPs identified in cancer and adjacent normal tissue.](pone.0070307.g001){#pone-0070307-g001}

After data analysis, we identified a total of 2342 sequence variations in the CRC and corresponding adjacent normal tissues. Among them, 738 were novel sequence variations based on comparisons with the current SNP database (dbSNP135; [Table S1](#pone.0070307.s002){ref-type="supplementary-material"}). 1226 variations were common to the CRC and normal colon tissues, while 374 and 742 variations were unique to each tissue type respectively ([Figure 1D](#pone-0070307-g001){ref-type="fig"}).

For the two pooled samples, the frequency of mutation rate ranged from 0.354 to 4.942 per kilobase for different genes. Most variations occurred in the intronic regions, with only 5% of the variations occurring in the exonic regions.

We randomly selected eight SNPs for validation covering variations found in intronic and in exonic regions. For validation, we used allele-specific PCR (AS-PCR) for genotyping single nucleotide polymorphisms [@pone.0070307-Wangkumhang1], [@pone.0070307-Ye1]. Each SNP was analyzed individually with a gene specific primer pair in a separate cohort of 22 CRC samples and 24 CRC adjacent normal tissues from the corresponding patients and four healthy donors ([Table S5](#pone.0070307.s006){ref-type="supplementary-material"}). We found that the data for four of the SNPs were consistent between the sequencing data and the PCR validation. For example, the SNPs for the MSX2 and KAT5 were detected 100% by the sequencing-based approach and by PCR validation. For rs80186078 in the TFDP1 gene, we only detected the SNP in the CRC tissues by sequencing and validating it in both CRC and CRN tissues but not in healthy donors by the AS-PCR validation. However, we also observed an inconsistency between the sequencing of the pooled samples and the PCR validation of individual samples. For example, rs11186694 and rs17107140 were detected in both CRC and CRN samples by sequencing but could not be detected by AS-PCR in individual samples. This result suggests a false positive identification of SNPs or a failure of the AS-PCR. We did not attempt to design additional PCR primers for AS-PCR, as we determined that AS-PCR was cumbersome and lacked sensitivity [@pone.0070307-Latorra1]. Furthermore, some of the SNPs (e.g., chr11∶65481267_TG) were detected in one pooled sample but were found in both CRC and normal tissues when analyzed by PCR validation of individual samples. This result suggests a false negative identification of SNPs in one of the pooled samples. However, it might not be surprising because if the allele frequency of the SNPs is low in one of the pooled samples, it might be missed by sequencing of pooled samples.

Due to the low efficiency and sensitivity of SNP validation by PCR, we decided to use the Sequenom MassARRAY iPLEX Platform for the validation studies. We chose 66 SNPs for validation in a separate cohort of 30 CRC tissues because the DNA used for sequencing was depleted. In the end, we were able to confirm the existence of 56 SNPS in the 30 CRC tissues ([Table S6](#pone.0070307.s007){ref-type="supplementary-material"}), suggesting a validation rate of at least 85% (56/66), considering that some of the detection failures might be due to differences in the sample population.

Functional Consequence of the Identified Sequence Variations {#s2b}
------------------------------------------------------------

We found 15 SNPs that would change protein sequences among the exonic variations in the CRC and normal colon tissues, including 14 missense mutations and 1 nonsense mutation ([Figure 1E](#pone-0070307-g001){ref-type="fig"} and [Table 2](#pone-0070307-t002){ref-type="table"}). These missense mutations may affect the function of the mutated protein products. The novel SNP chr13∶114288328_CT identified only in CRC tissues would result in a stop codon, which would cause early termination of the translation of TFDP1 (NP_009042, Q200\*) and loss of the Transc_factor_DP_C domain in the truncated TFDP1 protein. The effect of this truncated TFDP1 on CRC carcinogenesis remains to be investigated.

10.1371/journal.pone.0070307.t002

###### PolyPhen, SIFT and PROVEAN prediction results for non-synonymous variations identified.
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  SNP position           SNP ID     Protein   Acc. no.    Variation   Sample[a](#nt107){ref-type="table-fn"}       PolyPhen        SIFT (cutoff = 0.05)   PROVEAN (cutoff = −2.5)   Validated by Sequenom[b](#nt108){ref-type="table-fn"}                                 Previously identified as CRC mutation?
  -------------------- ----------- --------- ----------- ----------- ---------------------------------------- ------------------- ---------------------- ------------------------- ------------------------------------------------------- -----------------------------------------------------------------------------------------------------
  chr1∶78392446_GA      rs1166698    NEXN     NP_653174     G245R                    CRC; CRN                  Probably damaging         Damaging                 Neutral                                    \+                                                                             No
  chr11∶6340706_AG      rs1051992   PRKCDBP   NP_659477     L158P                    CRC; CRN                       Benign              Tolerated                 Neutral                                    \+                                                                             No
  chr5∶174156371_GA       Novel      MSX2     NP_002440     A197T                    --; CRN                   Probably damaging         Damaging               Deleterious                                   −                                                                             No
  chr5∶142779488_AG       Novel      NR3C1    NP_000167     F306S                    CRC; --                   Probably damaging        Tolerated                 Neutral                                     −                                                                             No
  chr5∶112176756_TA     rs459552      APC     NP_000029    V1822D                    CRC; CRN                       Benign              Tolerated                 Neutral                                     −                             Yes. Confers a protective effect with an odds ratio of 0.76 (CI = 0.60--0.97) among colon patients.
  chr6∶34214322_CG      rs1150781   C6orf1    NP_848603     G150A                    CRC; CRN                       Benign              Tolerated                 Neutral                                     −                                                                             No
  chr11∶65481267_TG       Novel      KAT5     NP_874369     V213G                    CRC; --                        Benign              Tolerated                 Neutral                                     −                                                                             No
  chr5∶174156168_TC     rs4242182    MSX2     NP_002440     M129T                    CRC; CRN                       Benign              Tolerated                 Neutral                                     −                                                                             No
  chr19∶1615796_GA      rs2074888    TCF3     NP_003191     A492V                    --; CRN                        Benign              Tolerated                 Neutral                                     −                                                                             No
  chr13∶114288328_CT      Novel      TFDP1    NP_009042    Q200\*                    CRC; --                          N/A                  N/A                      N/A                                       −                                                                             No
  chr6∶33283766_TC      rs3130100   ZBTB22    NP_005444     T310A                    CRC; CRN                       Benign              Tolerated                 Neutral                                     −                                                                             No

Tissue samples with SNP detected by NGS. CRC is the colorectal cancer tissue pool, and CRN is the colorectal cancer adjacent normal tissue pool.

"+"indicates "validated" and "−" indicated "not tested" by Sequenom.

Four of the mutations failed to be validated by Sequenom's MassARRAY iPLEX ([Table S6](#pone.0070307.s007){ref-type="supplementary-material"}) and were therefore excluded from further analysis. Four of the remaining 11 missense sequence variations identified in the CRC and normal colon tissues were novel mutations. The online tools PolyPhen, SIFT and PROVEAN were used to predict the functional consequences ([Table 2](#pone-0070307-t002){ref-type="table"}). All three programs predicted that the novel mutations for MSX2 (A197T) would affect the functional domains of the protein and might have functional consequences. The NEXN (G245R) variation was predicted to have functional consequences by the SIFT and PolyPhen programs ([Table 2](#pone-0070307-t002){ref-type="table"}). PolyPhen predicted another mutation in the NR3C1 gene to be likely damaging ([Table 2](#pone-0070307-t002){ref-type="table"}). We also assessed whether these 11 mutations have been previously reported for CRC. Ten of them have not been previously reported to be associated with CRC and therefore were identified for the first time ([Table 2](#pone-0070307-t002){ref-type="table"}). One of them, rs459552 in the APC gene has been reported to confer a protective effect for CRC with an odds ratio of 0.76 (CI = 0.60--0.97) among CRC patients [@pone.0070307-Picelli1].

There were 29 synonymous SNPs detected in the coding region in the CRC and CRN samples and 73 SNPs in the 5′ or 3′ UTR regions. FastSNP was used to predict the regulatory roles of these SNPs including exonic splicing enhancer (ESE), exonic splicing silencer (ESS), motif changes for synonymous SNPs ([Table 3](#pone-0070307-t003){ref-type="table"}), and TF binding sites changes for UTR SNPs ([Table 4](#pone-0070307-t004){ref-type="table"}). The ESE finder can identify ESEs recognized by individual SR proteins that are highly conserved splicing factors, and RESCUE-ESE can search sequences with ESE activity. In contrast, FAS-ESS can identify ESS. The prediction results from the three computational tools were combined to confirm whether the single nucleotide variation would change the splicing motif. The transcription factor binding sites associated with the target SNPs were identified by TFSEARCH using FastSNP. A total of 21 synonymous SNPs were predicted to change the exonic splicing motifs, and 31 UTR SNPs were predicted to occur at the transcription factor binding sites and therefore might affect gene transcription. The novel SNP chr2∶219524460_CA (5′UTR of BCSIL) was also found in conserved transcriptional binding sites ([Table S2](#pone.0070307.s003){ref-type="supplementary-material"}).

10.1371/journal.pone.0070307.t003

###### List of synonymous SNPs with ESE/ESS motifs changed.
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  Gene         SNP ID         SNP position      Sample[a](#nt109){ref-type="table-fn"}   Validated by Sequenom[b](#nt110){ref-type="table-fn"}
  --------- ------------- -------------------- ---------------------------------------- -------------------------------------------------------
  DAXX        rs1059231     chr6∶33288271_AG                   CRC;CRN                                            \+
  HIPK2       rs7456421    chr7∶139415775_CG                   CRC;CRN                                            \+
  APC         rs2229992    chr5∶112162854_TC                   CRC;CRN                                             −
  APC         rs351771     chr5∶112164561_GA                   CRC;CRN                                             −
  APC          rs41115     chr5∶112175770_GA                   CRC;CRN                                             −
  APC          rs42427     chr5∶112176325_GA                   CRC;CRN                                             −
  APC         rs866006     chr5∶112176559_TG                   CRC;CRN                                             −
  AXIN1       rs1805105     chr16∶396264_AG                    CRC;CRN                                             −
  ETS2        rs457705     chr21∶40191431_TG                   CRC;CRN                                             −
  ETS2        rs461155     chr21∶40191638_AG                   CRC;CRN                                             −
  FUBP1         Novel       chr1∶78422291_TG                    CRC;--                                             −
  NR3C1         Novel      chr5∶142779439_AG                   CRC;CRN                                             −
  PDIA2       rs432925      chr16∶334580_GC                     --;CRN                                             −
  PPARA      rs150197646   chr22∶46611153_TC                    CRC;--                                             −
  PRKCDBP      rs12570      chr11∶6340525_AT                   CRC;CRN                                             −
  STAT5A      rs1135669    chr17∶40459737_CT                   CRC;CRN                                             −
  TFDP1         Novel      chr13∶114294549_CT                  CRC;CRN                                             −
  TFDP1       rs4150756    chr13∶114277541_CT                   CRC;--                                             −
  TNKS2       rs3758499    chr10∶93608142_GA                   CRC;CRN                                             −
  TRIM28      rs2305120    chr19∶59059729_GA                    --;CRN                                             −
  ZSCAN21    rs11558476     chr7∶99654689_GA                   CRC;CRN                                             −

Tissue samples with SNP detected by NGS. CRC is the colorectal cancer tissue, and CRN is the colorectal cancer adjacent normal tissue.

"+"indicates "validated" and "−" indicated "not tested" by Sequenom.

10.1371/journal.pone.0070307.t004

###### List of UTR SNPs with transcription factor binding sites changed using TFSEARCH.
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  Region      Gene       SNP ID         SNP position      Sample[a](#nt111){ref-type="table-fn"}   Validated by Sequenom[b](#nt112){ref-type="table-fn"}
  -------- ---------- ------------- -------------------- ---------------------------------------- -------------------------------------------------------
  3′UTR       ETS2      rs1051425    chr21∶40195485_TC                   CRC;CRN                                            \+
  5′UTR      TAPBP     rs138551513    chr6∶33282002_CT                    --;CRN                                            \+
  3′UTR       APC        rs41116     chr5∶112180921_TC                   CRC;CRN                                             −
  3′UTR       APC       rs448475     chr5∶112181379_CG                   CRC;CRN                                             −
  3′UTR       APC       rs397768     chr5∶112181576_GA                   CRC;CRN                                             −
  5′UTR      BCS1L        Novel      chr2∶219524460_CA                    CRC;--                                             −
  3′UTR     C19orf26   rs36074840     chr19∶1230677_GA                   CRC;CRN                                             −
  3′UTR       ETS2        rs711      chr21∶40195059_AG                   CRC;CRN                                             −
  3′UTR       ETS2        rs530      chr21∶40195277_TA                   CRC;CRN                                             −
  3′UTR       FLI1      rs682695     chr11∶128682460_CA                  CRC;CRN                                             −
  3′UTR      GTF2A2     rs8027421    chr15∶59930865_AT                    --;CRN                                             −
  3′UTR      GTF2A2     rs8027679    chr15∶59930772_GC                   CRC;CRN                                             −
  3′UTR      HIPK2      rs1638195    chr7∶139252780_TC                   CRC;CRN                                             −
  3′UTR      HMGA1      rs2780219     chr6∶34212743_AG                    --;CRN                                             −
  3′UTR      HMGA1      rs1150782     chr6∶34213868_AG                    --;CRN                                             −
  3′UTR       MDM2        Novel      chr12∶69237323_CT                    --;CRN                                             −
  3′UTR       MDM2        Novel      chr12∶69235967_GA                    CRC;--                                             −
  3′UTR       MDM2      rs1132585    chr12∶69237388_AG                   CRC;CRN                                             −
  3′UTR       MSX2       rs14459     chr5∶174157711_AG                   CRC;CRN                                            \+
  3′UTR       MSX2      rs2890849    chr5∶174157762_GC                   CRC;CRN                                             −
  3′UTR       NEXN      rs3767028     chr1∶78408536_CG                    --;CRN                                             −
  3′UTR     RNASEH2C    rs535111     chr11∶65485337_AG                    --;CRN                                             −
  3′UTR     RNASEH2C    rs521678     chr11∶65485727_TG                   CRC;CRN                                             −
  3′UTR      STAT3      rs3744483    chr17∶40466438_TC                   CRC;CRN                                             −
  5′UTR      TAPBP     rs146763267    chr6∶33281842_GT                    --;CRN                                             −
  3′UTR       TCF3     rs41275834     chr19∶1609616_AT                   CRC;CRN                                             −
  3′UTR      TFDP1        Novel      chr13∶114294912_AT                   --;CRN                                             −
  3′UTR      TFDP1        Novel      chr13∶114295295_GA                   --;CRN                                             −
  3′UTR      TFDP1        Novel      chr13∶114294701_GT                   CRC;--                                             −
  3′UTR      TFDP1        Novel      chr13∶114295186_GA                   CRC;--                                             −
  5′UTR      ZNF142     rs4674324    chr2∶219523433_TG                   CRC;CRN                                             −

Tissue samples with SNP detected by NGS. CRC is the colorectal cancer tissue, and CRN is the colorectal cancer adjacent normal tissue.

"+" indicates "validated" and "−" indicated "not tested" by Sequenom.

To understand the functional consequences of the intronic SNPs, the online tool SNPnexus was used to annotate the SNPs. The distances to the splicing sites were computed by SNPnexus. There were 20 intronic SNPs located near the splicing sites with a distance less than 30 bp, and only one was novel. The mutations at these regions may affect splicing and transcription. C6orf1, ETV4, KAT5 and VAV1 each had two variations located near splicing sites, and TNKS2 had 3 variations located near splicing sites ([Table 5](#pone-0070307-t005){ref-type="table"}). The SNP rs2271959 (chr17∶41622740_GT, ETV4) was 5 bp away from the splicing site and was detected only in CRN tissues with high confidence. There were 43 intronic, upstream or intergenic SNPs in conserved transcription factor binding sites ([Table S2](#pone.0070307.s003){ref-type="supplementary-material"}) and 32 in CpG islands ([Table S3](#pone.0070307.s004){ref-type="supplementary-material"}).

10.1371/journal.pone.0070307.t005

###### Intronic SNPs near splice sites (\<30 nt).
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  SNP position          Gene    Acc. no.    Splice-dist. (bp)     SNP ID      Sample[a](#nt113){ref-type="table-fn"}   Validated by Sequenom[b](#nt114){ref-type="table-fn"}
  ------------------- -------- ----------- ------------------- ------------- ---------------------------------------- -------------------------------------------------------
  chr17∶41622740_GT     ETV4    NM_001986           5            rs2271959                    --;CRN                                            \+
  chr17∶41598940_TC     DHX8    NM_004941           7            rs2271957                   CRC;CRN                                            \+
  chr19∶1624007_AG      TCF3    NM_003200           8           rs55677929                   CRC;CRN                                            \+
  chr10∶93600480_GA    TNKS2    NM_025235          17           rs17107140                   CRC;CRN                                            \+
  chr17∶41623212_GA     ETV4    NM_001986          17           rs79158595                    --;CRN                                            \+
  chr10∶93572984_CT    TNKS2    NM_025235          20           rs11186694                   CRC;CRN                                            \+
  chr21∶40193488_GA     ETS2    NM_005239          22           rs117862776                   --;CRN                                            \+
  chr19∶59059798_CT    TRIM28   NM_005762          23              Novel                      --;CRN                                            \+
  chr11∶65481166_TC     KAT5    NM_182710          28            rs1151500                   CRC;CRN                                            \+
  chr11∶71804513_GA    LRTOMT   NM_145309          29            rs2250866                   CRC;CRN                                            \+
  chr5∶112170870_TC     APC     NM_000038           8           rs62626346                    --;CRN                                             −
  chr19∶6822219_TC      VAV1    NM_005428          13            rs347033                     --;CRN                                             −
  chr5∶142680344_CA    NR3C1    NM_000176          16             rs6188                      CRC;--                                             −
  chr6∶34215228_GA     C6orf1   NM_178508          16            rs1150780                    --;CRN                                             −
  chr10∶93617306_AG    TNKS2    NM_025235          19            rs1340420                   CRC;CRN                                             −
  chr16∶359953_AG      AXIN1    NM_003502          20            rs2301522                    --;CRN                                             −
  chr2∶219527005_CT    BCS1L    NM_004328          22            rs2303561                    --;CRN                                             −
  chr6∶34215221_GA     C6orf1   NM_178508          23            rs928482                     --;CRN                                             −
  chr19∶6833989_GT      VAV1    NM_005428          25            rs308199                    CRC;CRN                                             −
  chr11∶65480791_AG     KAT5    NM_006388          28            rs551115                    CRC;CRN                                             −

Tissue samples with SNP detected by NGS. CRC is the colorectal cancer tissue, and CRN is the colorectal cancer adjacent normal tissue.

"+" indicates "validated" and "−" indicated "not tested" by Sequenom.

The public ChIP-seq datasets, especially the ENCODE project, provide vast TF binding or DNAase hypersensitivity sites in various cell lines. Here, we used RegulomeDB to annotate the SNPs with regulatory regions. Each SNP was given a score that represented different regulatory regions by RegulomeDB ([Table S1](#pone.0070307.s002){ref-type="supplementary-material"}, [Table 6](#pone-0070307-t006){ref-type="table"}). The aforementioned, likely damaging, missense SNP rs1166698 (NEXN, validate by Sequenom) received a score of 1b, which was the highest in this study, indicating that the SNP was involved in many important regulatory regions. Another 1b SNP was rs1860661, located in the intron of TCF3 and not tested by Sequenom. Among the 2342 SNPs, 1062 were situated in TF binding regions defined by ChIP-seq technology.

10.1371/journal.pone.0070307.t006

###### Overview of RegulomeDB annotation.
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  Score    SNP Counts                        Supporting data sets
  ------- ------------ ----------------------------------------------------------------
  1b           2             eQTL+TF binding+any motif+DNase Footprint+DNase peak
  1d           4                     eQTL+TF binding+any motif+DNase peak
  1f           26                         eQTL+TF binding/DNase peak
  2a           10       TF binding+matched TF motif+matched DNase Footprint+DNase peak
  2b           52              TF binding+any motif+DNase Footprint+DNase peak
  2c           2                    TF binding+matched TF motif+DNase peak
  3a           47                      TF binding+any motif+DNase peak
  4           243                           TF binding+DNase peak
  5           676                          TF binding or DNase peak
  6           510                                   Other
  7           770                                  No data

Analysis of Associations between SNPs and Overall Survival Time {#s2c}
---------------------------------------------------------------

We chose nine SNPs ([Table 7](#pone-0070307-t007){ref-type="table"}) that were validated by the Sequenom MassARRAY iPLEX technology and with allele heterozygosities of greater than 0.4 for analysis of the association between SNPs and CRC patient survival. We collected samples from a set of 117 patients with detailed clinical information for this analysis using the Sequenom MassARRAY iPLEX technology. The distribution of the 117 patients' demographic and clinicopathologic characteristics are summarized in [Table 8](#pone-0070307-t008){ref-type="table"}, and the genotype data are summarized in [Table S7](#pone.0070307.s008){ref-type="supplementary-material"}.

10.1371/journal.pone.0070307.t007

###### The association of single SNP with CRC patient survival.
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                                                   death/total   dominant   additive              recessive                                                                                                        
  -------- --- ----- ------------ --------------- ------------- ---------- ---------- --------------------------------- ----------- --------------------------------- ----------- -------------------------------- -------
  TAPBP     C   C/T   rs3106189        5′UTR          20/65       12/42       1/7      0.2489404(0.0871363--0.7112003)   **0.009**   0.3289281(0.1279939--0.8453038)   **0.021**   0.7882852(0.0967128--6.425145)   0.824
  TCF3      T   C/T   rs1052918        3′UTR          12/37       12/47       5/22     0.2802584(0.0926905--0.8473875)   **0.024**   0.5921091(0.2649582--1.323202)      0.201     1.076675(0.3393056--3.416473)     0.9
  ETV4      A   A/G   rs79868029     intronic         14/46       13/47       6/13      1.746839(0.6486287--4.704459)      0.27       1.453808(0.7773533--2.718915)      0.241      1.720894(0.5184039--5.71268)    0.375
  ETV4      G   A/G   rs79158595     intronic         15/46       11/45       6/14      1.238529(0.4701443--3.26273)       0.665      1.249898(0.6641922--2.352096)      0.489      1.676421(0.4922574--5.70918)    0.409
  DHX8      T   C/T   rs71361531     intronic         14/45       13/54       7/14      1.722156(0.6399157--4.634706)      0.282      1.516384(0.8136795--2.825954)      0.19      2.006176(0.6380821--6.307564)    0.234
  NEXN      G   A/G   rs1166698    coding(G\|R)       14/37       15/54       3/18     0.7786868(0.2625501--2.309476)      0.652     0.8774619(0.3942656--1.952844)      0.749     1.002838(0.2277706--4.415333)    0.997
  HIPK2     C   G/C   rs7456421    coding(V\|V)       1/11        11/51      23/53      1.491145(0.2662636--8.350797)      0.649      1.507939(0.7196225--3.159823)      0.276     1.836416(0.6948774--4.853267)    0.22
  STAT5A    T   C/T   rs1053023    3′ downstream      14/40       16/62       2/8      0.4510602(0.1703864--1.194082)      0.109      0.5324628(0.2144653--1.32197)      0.174     0.8564487(0.102282--7.171397)    0.886
  ETS2      T   C/T   rs1051425        3′UTR           0/3        14/42      20/67                  omit                              2.06858(0.7675036--5.575248)       0.151                  omit                  ?

Note: The significant P values (≤0.05) are in bold.

WW, homozygous wild-type genotype; WV heterozygous genotype; VV, homozygous variant genotype.

Abbreviations: CI, confidence interval; HR, hazard ratio; omit, no results due to missing information on the death status.

10.1371/journal.pone.0070307.t008

###### The clinicopathological characteristics of 117 Chinese CRC patients.
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  Variables                Number of patients   \% (n = 117)  
  ----------------------- -------------------- -------------- --------
  Age                           \> = 60              71        60.68%
                                  \<60               46        39.32%
  Gender                          Male               69        58.97%
                                 Female              48        41.03%
  Tumor position                 Colon               66        56.41%
                                 Rectum              51        43.59%
  Tumor differentiation           Poor               4         3.42%
                                Moderate             37        31.62%
                                  Well               53        45.30%
                             Not available           23        19.66%
  Infiltration depth       Outside of serosa         31        26.50%
                                 Serosa              47        40.17%
                                Propria              21        17.95%
                                 Mucosa              2         1.71%
                             Not available           16        13.68%
  Positive lymph node             Null               60        51.28%
                                  \>0                37        31.62%
                             Not available           20        17.09%
  Tumor stage                      I                 18        15.38%
                                   II                45        38.46%
                                  III                41        35.04%
                                   IV                13        11.11%

We first analyzed the Hardy-Weinberg equilibrium of each SNP and found that only SNP rs1053023 deviated from the Hardy-Weinberg equilibrium ([Table 9](#pone-0070307-t009){ref-type="table"}, p\<0.05); the P values for other SNPs ranged from 0.3265 to 1. The effect of the nine SNPs on overall survival time was assessed in 117 CRC patients using the Kaplan-Meier method and plotted using the Stata 12 ([www.stata.com](http://www.stata.com)) statistical analysis program. We found that two SNPs (rs3106189 and rs1052918) were associated with overall survival of CRC patients ([Figure 2](#pone-0070307-g002){ref-type="fig"}) using the dominant model with hazard ratios of 0.25 (P = 0.009) and 0.28 (P = 0.024), respectively. The SNP rs3106189 was also significantly associated with CRC patient survival with the additive model (hazard ratio = 0.33, P = 0.021; [Table 7](#pone-0070307-t007){ref-type="table"}). The SNP rs3106189 localized to the 5′ UTR of TAPBP, and the SNP rs1052918 localized to the 3′ UTR of the TCF3. For the SNP rs3106189, the numbers of patients with heterozygous and homozygous variants were 42 and 7 respectively. For the SNP rs1052918, the numbers of patients with heterozygous and homozygous variants were 47 and 22 respectively. Patients bearing one of the two variants seem to have higher probabilities to survive longer.

![Colorectal cancer overall survival in relationship to SNPs.\
(A) Kaplan-Meier plot for rs3106189 localized to the 5′ UTR of TAPBP. (B) Kaplan-Meier plot for rs1052918 localized to the 3′ UTR of the TCF3. Y-axis, CRC survival probability; X-axis, months from surgery. Blue lines are homozygous wildtype (wild), green are homozygous variant (var), red are heterozygous variant (het).](pone.0070307.g002){#pone-0070307-g002}

10.1371/journal.pone.0070307.t009

###### The Hardy-Weinberg equilibrium of the SNPs.
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  SNP ID        Gene Name   Pearson chi2   P-value   LR chi2   P-value   Exact Significance
  ------------ ----------- -------------- --------- --------- --------- --------------------
  rs1053023       STAT3        5.895       0.0152     6.185    0.0129        **0.0215**
  rs1052918       TCF3         0.958       0.3276     0.958    0.3278          0.3265
  rs1051425       ETS2         1.446       0.2291     1.588    0.2076          0.3963
  rs79158595      ETV4         0.319       0.5724     0.317    0.5736          0.6663
  rs79868029      ETV4         0.034       0.8527     0.034    0.8529          0.8319
  rs71361531      DHX8         0.127       0.7215     0.128    0.7209          0.8395
  rs3106189       TAPBP        0.004       0.9505     0.004    0.9506            1
  rs1166698       NEXN         0.052       0.8193     0.052    0.8193            1
  rs7456421       HIPK2        0.063       0.8013     0.064    0.8008            1

Discussion {#s3}
==========

In this manuscript, we describe our analysis pipeline that consists of (1) initially sequencing pooled DNA samples followed by validation and further analysis in larger cohorts of samples for cost reduction and (2) a hypothesis-driven targeted capturing and analysis of SNPs and their associations with the cancer phenotypes. Pooling genomic DNAs for sequencing has the advantage of reducing sample preparation and sequencing costs. For example, capturing 30 individual samples would require using 30 capture arrays to perform hybridization and sample recoveries, which are tedious and may potentially introduce sample-to-sample variations during the sample preparation stage. Sequencing 30 individual samples would also be substantially more costly than sequencing one pool. Although it is possible to use barcoding and multiplexing reactions and sequencing to achieve similar sequence coverage at a similar cost to pooling samples, the sample preparation complexity would be substantially higher. In a recent GWAS analysis of type 1 diabetes (T1D) published in Science, Nejentsev *et al.* re-sequenced exons and splice sites of 10 candidate genes in DNA pools from 480 patients and 480 controls to identify causative type 1 diabetes (T1D) variants and then tested their disease association in over 30,000 participants [@pone.0070307-Nejentsev1]. The authors were able to identify four rare variants that independently lowered T1D risk \[odds ratios, 0.51 to 0.74; P = 1.3×10(−3) to 2.1×10(−16)\] in interferon induced with helicase C domain 1 (IFIH1) [@pone.0070307-Nejentsev1].

Another distinct feature of our analysis pipeline is that we sequenced the genomic regions that included exonic and intronic regions, i.e., the 10-kb promoter and the 5-kb downstream genomic regions of the selected genes. This method was in contrast with most studies that only analyzed the exonic sequences (exome capture) [@pone.0070307-Chaki1], [@pone.0070307-Ng1]. It is important to include the promoter regions in the analysis, as SNPs in the promoter regions have been associated with tumorigenesis. For example, Bond *et al.* showed that a single nucleotide polymorphism in the MDM2 promoter could attenuate the p53 tumor suppressor pathway and accelerate tumor formation in humans [@pone.0070307-Bond1]. Passarelli *et al.* showed that SNPs in the estrogen receptor beta promoter are associated with survival of postmenopausal women with CRC [@pone.0070307-Passarelli1]. Polymorphisms in the UTR regions of genes have also been found to be related to cancer. For example, Zhang *et al.* found that a polymorphism in the 3′UTR region of insulin-like growth factor I (IGF1) gene predicts survival of non-small cell lung cancer in a Chinese population [@pone.0070307-Zhang1]. Hao *et al.* found that a SNP (rs3213245, −77T\>C) in the XRCC1 gene 5′ UTR contributes to diminished promoter activity and increased risk of non-small-cell lung cancer [@pone.0070307-Hao1]. We have identified and validated using Sequenom's platform several SNPs that localized to the 5′ or 3′ UTR of the genes ([Table S6](#pone.0070307.s007){ref-type="supplementary-material"}). For example, rs3106189 of TAPBP and rs8041394 of GTF2A2 localized to 5′ UTRs, and rs1051425 of ETS2 and rs1052918 of TCF3 localized to 3′UTRs ([Table S6](#pone.0070307.s007){ref-type="supplementary-material"}). The functional significance of these SNPs remains to be determined.

We have chosen genes related to the WNT pathway, as the Cancer Genome Atlas Network found mutations in 16 different genes in the WNT pathways including APC, CTNNB1, FAM123B and TCF7L2 [@pone.0070307-Network1]. We extended the analysis of the WNT pathway genes to regions beyond the exome analyzed the Cancer Genome Atlas Network, and our approach has the potential to identify those mutations that modulate gene expression or splicing in additional to the identification of those structurally damaging mutations in the exons.

We identified a total of 2342 sequence variations in CRC and corresponding adjacent normal tissues. Among them, 738 were novel sequence variations based on comparison with the current SNP database (dbSNP135; [Table S1](#pone.0070307.s002){ref-type="supplementary-material"}). We chose 66 SNPs for validation in a separate cohort of 30 CRC tissues. We were able to confirm the existence of 56 SNPS in the 30 CRC tissues ([Table S6](#pone.0070307.s007){ref-type="supplementary-material"}), suggesting a validation rate of at least 85% (56/66), considering that some of detection failures might be due to differences in the sample population. This validation rate is in line with the published validation rate of 85.4% for NGS using the Illumina platform [@pone.0070307-You1]. In addition, it has been reported that various validation platforms including the Sanger sequencing, Pyrosequencing, Sequenom MassArray or SNAPshot SNP Detection lack the sensitivity to confirm sequence variants identified by deep sequencing in tumors, which may be contaminated with DNAs from normal tissues or which may contain multiple clones [@pone.0070307-Wagle1].

We identified 14 missense exonic mutations in the CRC and normal colon tissues ([Table 2](#pone-0070307-t002){ref-type="table"}). The SNP (G245R) at the NEXN gene (Nexilin; F actin binding protein) was predicted to have functional consequences. The roles of the NEXN gene in cancer have not yet been investigated. Two novel SNPs in the nuclear receptor subfamily 3, group C, member 1 (NR3C1) and lysine acetyltransferase 5 (KAT5) genes were found only in CRC tissues but not in normal colon tissues. KAT5 (also named TIP60 or HIV-1-Tat interactive protein) is a histone acetyl transferase (HAT), and it plays important roles in regulating chromatin remodeling and in DNA repair and apoptosis [@pone.0070307-Ikura1]. In colorectal cancers, KAT5 down regulation is associated with more advanced stages of colorectal cancer [@pone.0070307-Sakuraba1]. NR3C1 (alias, glucocorticoid receptor) was found to be epigenetically deregulated in colorectal tumorigenesis [@pone.0070307-Lind1]. Furthermore, hypermethylated NR3C1 is a CRC gene with microsatellite instability [@pone.0070307-Ahlquist1]. These novel SNPs in the KAT5 and NR3C1 genes warrant confirmation, and additional functional studies are needed to assess the functional consequences of the mutations and their relationship to cancer, such as whether the SNPs would mimic the epigenetic regulations of these genes.

We also identified SNPs that might affect exon splicing because they localize to the ESE (exonic splicing enhancer) and ESS (exonic splicing silencer), which are critical in exon splicing. For example, we identified SNPs in the far upstream element (FUSE) binding protein 1 (FUBP1), peroxisome proliferator-activated receptor alpha (PPARA) and transcription factor Dp-1 (TFDP1) that might affect exon splicing for these genes, and these SNPs were found only in the CRC tissues ([Table 3](#pone-0070307-t003){ref-type="table"}). Zhang *et al.* showed that a SNP (−195 C\>T; dbSNP ID: rs1056932) that alters a potential binding site for an exonic splicing enhancer could affect the risk of non-Hodgkin lymphoma [@pone.0070307-Zhang2]. The functional consequences of the SNPs that localize to the ESE or ES sequences in FUBP1, PPARA and TFDP1 genes warrant further investigation.

We determined that rs3106189, localized at the 5′ UTR of TAP binding protein (tapasin; TAPBP), and rs1052918, localized at the 3′ UTR of the TCF3, were associated with overall survival of CRC patients ([Table 7](#pone-0070307-t007){ref-type="table"} and [Figure 2](#pone-0070307-g002){ref-type="fig"}) with hazard ratios reaching 0.28 (P = 0.024) and 0.33 (P = 0.021) respectively. These data suggest that these two variants confer protective effects for CRC patients. Interestingly, another variant that we identified, the rs459552 in the APC gene, was previously reported to confer a protective effect for CRC with an odds ratio of 0.76 (CI = 0.60--0.97) among CRC patients [@pone.0070307-Picelli1]. However, we did not analyze this SNP by the Sequenom technology and therefore could not assess whether the finding is also true in our data set.

TAPBP encodes a transmembrane glycoprotein that mediates the interaction between newly assembled major histocompatibility complex (MHC) class I molecules and the transporter associated with antigen processing (TAP) [@pone.0070307-Ortmann1]. Downregulation of TAPBP expression has been observed for multiple cancers, including CRC, as an immune escape mechanism of human tumors [@pone.0070307-Seliger1]. Loss of TAPBP expression has been observed in 80% of high-grade intraepithelial neoplasia (HIN) compared with autologous colorectal mucosa, in 63% of primary adenocarcinomas in stage III and 79% of the matched lymph node metastases [@pone.0070307-Atkins1]. The ex vivo introduction of TAPBP expression in a murine lung carcinoma model increased surface MHC class I and restored susceptibility of tumor cells to antigen-specific cytotoxic T lymphocytes (CTL) killing [@pone.0070307-Lou1]. The SNP rs3106189 is located within an H3K27Ac histone mark, which is often found near active regulatory elements, and within H3K9Ac and H3K4me3 marks (UCSC genome browser; [Figure S1](#pone.0070307.s001){ref-type="supplementary-material"}). Furthermore, rs3106189 is localized among binding sites for several transcription factors including interferon regulatory transcription factor 1 (IRF-1), IRF-2 and IRF-7. The exact functional consequence of the variant at the rs3106189 locus requires further study.

Transcription factor 3 (TCF3; E2A immunoglobulin enhancer binding factors E12/E47) is a member of the TCF/LEF transcription factor family that is central in regulating epidermal and embryonic stem cell identity and is involved in the WNT signaling pathway [@pone.0070307-Slyper1]. In breast cancer, TCF3 is involved in the regulation of breast cancer cell differentiation state and tumorigenicity [@pone.0070307-Slyper1]. Furthermore, overexpression of TCF3 is partially responsible for the butyrate-resistant phenotype of CRC because TCF3 suppresses the hyper-induction of Wnt activity by butyrate [@pone.0070307-Chiaro1]. The functional consequence of the variant at rs1052918, which is localized at the 3′ UTR of the TCF3, remains to be determined.

Materials and Methods {#s4}
=====================

Ethics Statement {#s4a}
----------------

Informed written consent was obtained from each patient, and the ethics committee of the Second Affiliated Hospital, College of Medicine and Zhejiang University approved all aspects of the study.

Clinical Samples and Genomic DNA Isolation {#s4b}
------------------------------------------

Tissue samples were obtained from four control subjects (healthy individuals) and 30 colorectal cancer patients for the first cohort and 117 CRC patients for the validation study. All subjects were Chinese, and the samples were collected at the Second Affiliated Hospital, Zhejiang University. The DNA samples were isolated using the DNeasy Blood & Tissue Kit (QIAGEN Inc., Valencia CA) according to the manufacturer's protocol.

NimbleGen Sequence Capture {#s4c}
--------------------------

Genomic DNAs from 30 colon cancer patients were mixed in equal ratios and the DNA pools were captured on a custom NimbleGen 385K array following the manufacturer's protocol (Roche/NimbleGen, Madison, WI) with modifications at the W. M. Keck Facility at Yale University. A custom tiling 385K sequence capture array targeting genomic sequence for all the 28 genes (including 10-kb upstream and 5-kb downstream regions) was designed and manufactured by Roche NimbleGen. Briefly, the genomic DNA sample was fragmented and hybridized to the custom NimbleGen Sequence Capture array. Unbound fragments were removed, and the target-enriched DNA was eluted and amplified.

The captured DNA was sheared through sonication, and adapters were ligated to the resulting fragments. The adapter-ligated templates were fractionated by agarose gel electrophoresis, and the fragments of the desired size were excised. The extracted DNA was amplifed using ligation-mediated PCR, purifed, and hybridized to the capture array at 42.0°C using the manufacturer's buffer. The array was washed twice at 47.5°C and three times at room temperature using the manufacturer's buffers. Bound genomic DNA was eluted using 125 mM NaOH for 10 min at room temperature, purifed, and amplifed through ligation-mediated PCR. The resulting fragments were purifed and subjected to DNA sequencing on the Illumina platform. Captured and non-captured amplifed samples were subjected to quantitative PCR to measure the relative fold enrichment of the targeted sequence.

Sequence Analyses by the Next Generation Sequencing Technology {#s4d}
--------------------------------------------------------------

Amplified DNA samples were sonicated for 10 minutes (130 w, Cole-Parmer CPX 130, Illinois USA) to generate DNA fragments with an average size of 500 base pairs (bp). The fragments were further purified and concentrated with Qiaquick PCR purification spin columns (QIAGEN Inc., Valencia CA). Genomic fragments were end-repaired with a mixture of T4 DNA polymerase, Klenow DNA polymerase and T4 PNK (Promega, Madison, WI USA), and a 3′ overhang A was added using Klenow exo-enzyme (Promega, Madison, WI USA). The resultant fragments were ligated with the Illumina classical adapters by DNA T4 ligase (Promega, Madison, WI USA) according to Illumina's protocol. Adapter-linked DNA fragments were separated by agarose gel electrophoresis, and the band between 150 and 200 bp was excised from the gel. The DNA fragments were extracted from the agarose slices using the Qiaquick Gel Extraction Kit (Qiagen Inc.). Extracted DNA was enriched by an 18-cycle amplification using Illumina's universal adapters. The DNA fragments were purified and quantified and then sequenced for 40 cycles using Illumina's protocol.

Short Read Mapping and SNP Calling {#s4e}
----------------------------------

Short-sequence reads were extracted from the image files with the Illumina GAPipeline 1.4.0 and mapped to the genome sequence using BWA (version 0.5.3) with default parameters. BWA is an efficient program for aligning relatively short nucleotide sequences against a long reference sequence allowing mismatches, thus detecting SNPs [@pone.0070307-Li1].

SNPs were identified by SAMtools (version 0.1.6), which migrated and improved various downstream data processing implemented in Maq/Maqview such as indexing, pileup, viewer and consensus caller. SAMtools generated the consensus sequence with the statistical model implemented in MAQ [@pone.0070307-Li2], [@pone.0070307-Li3]. Potential PCR duplicates were first removed by the command "samtools rmdup". Raw variations were called by the command "samtools pileup" with default parameters and then filtered by the command "samtools.pl varFilter" with default options except for the following: minimum read depth (-d 5) to filter out low covered regions, maximum read depth (-D 255) to filter out randomly placed repetitive hits. Those SNPs with an SNP quality greater than 45 were considered high quality and were used for subsequent analysis.

Detecting Regions of no or Low Read Coverage {#s4f}
--------------------------------------------

Regions of no or low read coverage can be caused by either ineffective sequence capture or inaccuracy in short reads mapping. GC content can affect Solexa base calling and PCR amplification. In addition, low complexity regions can affect short reads mapping. GC content and read coverage were computed in an 81-bp window.

Prediction of Functional Consequences of SNPs {#s4g}
---------------------------------------------

The final filtered SNPs were annotated using ANNOVAR [@pone.0070307-Wang1] to identify the gene region to which the SNPs located. The online tool SNPnexus was then used for functional annotation for all the SNPs. SNPnexus is a database providing a complete set of functional annotations of SNPs including consequences to genes and regulatory elements [@pone.0070307-Chelala1]. PolyPhen [@pone.0070307-Ramensky1], SIFT [@pone.0070307-Ng2]--[@pone.0070307-Kumar1] and PROVEAN [@pone.0070307-Choi1] were used for prediction of functional effect of human nsSNPs. Another online tool, FastSNP [@pone.0070307-Yuan1], was used to predict exonic splicing enhancer/silencer motifs changed by the SNP alleles by integrating results from ESEfinder [@pone.0070307-Cartegni1], RESCUE-ESE [@pone.0070307-Fairbrother1] and FAS-ESS [@pone.0070307-Wang2] and transcription factor binding sites alteration by TFSEARCH. Moreover, all the SNPs were searched against RegulomeDB to determine involvement in regulatory DNA elements including regions of DNAase hypersensitivity, binding sites of transcription factors, and promoter regions obtained from public ChIP-seq datasets [@pone.0070307-Boyle1].

SNP Genotyping {#s4h}
--------------

SNP Genotyping Using the Sequenom MassARRAY iPLEX Platform was conducted by the Beijing Genomic Institute (BGI, Shenzhen) according to the manufacturer's protocol, as previously described [@pone.0070307-Zhou1]. Briefly, PCR primers and extension probes were designed using the Sequenom MassARRAY Assay Design 3.0 software. PCR amplification and single-base extension were performed. The purified extension products were dispensed onto a Spectro-CHIP bioarray and analyzed using a MALDI-TOF mass spectrometer. The data were analyzed using the MassARRAY Workstation software (version 3.3). Laboratory personnel conducting the genotyping were blinded to patient information. Strict quality control measures were implemented during genotyping with over 98% concordance between samples genotyped in duplicate.

Statistical and Data Analysis {#s4i}
-----------------------------

Overall survival analysis was conducted using Stata 12. The overall survival time was defined as the month from initial surgery to death from any cause. The relationship between the survival time and an allele was assessed using the Kaplan-Meier method and plotted using Stata 12. All patients alive or lost were censored for analysis. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated from a multivariate Cox proportional hazards model, adjusting for age, gender, tumor position, differentiation, tumor stage, positive lymph node status, and infiltration depth, adopting three genetic models (dominant, recessive, and additive). The Hardy-Weinberg equilibrium (HWE) for each SNP was determined using the hwsnp function in Stata 12.

Confirmation of the Variations {#s4j}
------------------------------

To confirm SNPs identified by the next-generation sequencing techniques, we performed allele-specific PCR (AS-PCR) [@pone.0070307-Wangkumhang1], [@pone.0070307-Ye1] in a cohort of 46 samples of individual colorectal cancer samples and 4 healthy volunteers. We employed AS-PCR, which is an efficient procedure for genotyping single nucleotide polymorphisms developed by Ye *et al.* [@pone.0070307-Wangkumhang1], [@pone.0070307-Ye1]. In brief, primers ([Table S4](#pone.0070307.s005){ref-type="supplementary-material"}) were designed using an online program for designing AS-PCR primers (<http://cedar.genetics.soton.ac.uk/public_html/primer1.html>) [@pone.0070307-Ye1]. Each PCR reaction was performed in a total volume of 10 µl, containing a final concentration of 1× TAKARA Ex Taq Buffer, 2.5 mM Mg^2+^, 250 µM of each dNTP,0.2 µM of each primer and 5 U/µl TaKaRa Ex Taq polymerase. The results were analyzed using 2% agarose gel electrophoresis.

Supporting Information {#s5}
======================

###### 

**The landscape of the two SNPs viewed by the UCSC genome browser.** (A) rs3106189 at the 5′ UTR of TAPBP. (B) rs1052918 at the 3′ UTR of TCF3. The red boxes represent the target SNP sites. Each row represents a regulatory element in UCSC genome browser such as the surrounding SNPs, binding region from ChIP-seq by ENCODE project and conservation scores.
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Click here for additional data file.
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**List of SNPs identified in CRC patients.**
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**List of SNPs locating in conserved transcription factor binding sites.**
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**List of SNPs locating in CpG islands.**
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Click here for additional data file.
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**List of primers used for SNP validation.**
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Click here for additional data file.
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**SNP validation of 8 randomly selected SNPs.**
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Click here for additional data file.
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**SNP Genotyping using the Sequenom MassARRAY iPLEX platform in 30 CRC patients.**

(XLSX)
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Click here for additional data file.
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**SNP genotyping using the Sequenom MassARRAY iPLEX platform in 117 CRC patients.**

(XLSX)

###### 

Click here for additional data file.
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